

- S1. Teyssier, J.R., et al. 1986. Recurrent deletion of the short arm of chromosome 3 in human renal cell carcinoma: shift of the c-raf 1 locus. *J. Natl. Cancer Inst.* 77:1187-1195.
- S2. Nagy, A., Balint, I., and Kovacs, G. 2003. Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. *Int. J. Cancer.* 106:980-981.
- S3. Fong, T.A., et al. 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. *Cancer Res.* 59:99-106.
- S4. Hu-Lowe, D., et al. 2002. Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736. *Proc. Am. Assoc. Cancer. Res.* [abstract]. 43:A5357.
- S5. Stopeck, A., et al. 2002. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. *Clin. Cancer Res.* 8:2798-2805.
- S6. Rugo, H.S., et al. 2004. Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. *2004 ASCO Annual Meeting Proceedings.* June 5–8, 2004. *J. Clin. Oncol.* [abstract]. 22:2503.
- S7. Peterson, A.C., et al. 2004. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. *Clin. Cancer Res.* 10:4048-4054.
- S8. Mitjans, F., et al. 2000. In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. *Int. J. Cancer.* 87:716-723.
- S9. Holden, S.N., Morrow, M., O'Bryant, C., Pluda, J., and Eckhardt, S.G. 2002. Correlative biological assays used to guide dose escalation in a phase I study of the antiangiogenic $\alpha V\beta 3$ and $\alpha V\beta 5$ integrin antagonist EMD 121974 (EMD). *2002 ASCO Annual Meeting Proceedings.* May 18–21, 2002. [abstract 110]. 21:28a.
- S10. Dillon, B.J., et al. 2004. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. *Cancer.* 100:826-833.

- S11. Ensor, C.M., Holtsberg, F.W., Bomalaski, J.S., and Clark, M.A. 2002. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. *Cancer Res.* 62:5443-5450.
- S12. Logan, T., et al. 2003. Phase I/II testing of pegylated arginine deiminase in metastatic melanoma. *Proc Am Soc Clin Oncol* 22:710 [abstract 2855].
- S13. Vassilev, L.T. 2004. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. *Cell Cycle.* 3:419-421.
- S14. Flaherty, K.T. 2004. New molecular targets in melanoma. *Curr. Opin. Oncol.* 16:150-154.
- S15. Dellavalle, R.P., Nicholas, M.K., and Schilling, L.M. 2003. Melanoma chemoprevention: a role for statins or fibrates? *Am. J. Ther.* 10:203-210.
- S16. Demierre, M.F., and Merlino, G. 2004. Chemoprevention of melanoma. *Curr. Oncol. Rep.* 6:406-413.
- S17. Lewis, J.J. 2004. Therapeutic cancer vaccines: using unique antigens. *Proc. Natl. Acad. Sci. U. S. A.* **101**(Suppl. 2):14653-14656.
- S18. Ramirez, R.D., et al. 1999. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma. *Neoplasia.* 1:42-49.
- S19. Pirker, C., et al. 2003. Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. *Melanoma Res.* 13:483-492.
- S20. Nosrati, M., et al. 2004. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA. *Clin. Cancer Res.* 10:4983-4990.
- S21. Eller, M.S., Puri, N., Hadshiew, I.M., Venna, S.S., and Gilchrist, B.A. 2002. Induction of apoptosis by telomere 3' overhang-specific DNA. *Exp. Cell Res.* 276:185-193.
- S22. Li, G.Z., Eller, M.S., Hanna, K., and Gilchrist, B.A. 2004. Signaling pathway requirements for induction of senescence by telomere homolog oligonucleotides. *Exp. Cell Res.* 301:189-200.
- S23. Du, J., et al. 2004. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. *Cancer Cell.* 6:565-

576.

S24. Herlyn, M., and Shih, I.M. 1994. Interactions of melanocytes and melanoma cells with the microenvironment. *Pigment Cell Res.* 7:81-88.

S25. Mitjans, F., et al. 1995. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. *J. Cell Sci.* 108:2825-2838.

S26. Jansen, B., et al. 2000. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. *Lancet.* 356:1728-1733.

S27. Belli, B., Deckworth, T., S., A.A., and al., e. 2003. A-385358, a potent Bcl-x1/Bcl-2 antagonist induces apoptosis in tumor cell lines [abstract]. *Proc AACR* 44:abstract LB-150. who wrote this

S28. Kim, R., Emi, M., Tanabe, K., and Toge, T. 2004. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. *Cancer.* 101:2491-2502.

S29. Omenn, G.S. 2002. Genetic advances will influence the practice of medicine: examples from cancer research and care of cancer patients. *Genet. Med.* 4:15S-20S.

S30. Tsao, H., Sober, A.J., Niendorf, K.B., and Zembowicz, A. 2004. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2004. A 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. *N. Engl. J. Med.* 350:924-932.